CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Understanding what to expect in financial planning for 2025 is crucial for adapting your strategies. Stay informed and ready.
22,201 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A top AI firm treads a thin line: warning about AI power while pushing new, powerful tools to market. This raises que...
When Anthropic faced a backlash over secret censorship in Claude Fable 5, the company apologized and promised safegua...
AI is rewriting investing playbooks. This piece uncovers a prophetic phrase from IBM and shows how it can inform smar...
As UnitedHealth readies its 2026 earnings, investors want clarity on growth, margins, and risk. This guide breaks dow...
If president donald trump just signals a major crypto push, investors face a fast-moving regulatory landscape. This g...
Oscars night still draws attention, but audiences now treat it like leftovers—snippets on social media instead of a s...
A May 2026 poll defines a new voter cohort—the disillusioned—showing widespread financial strain and a belief that th...
A recent internal survey found that nearly half of Harvard seniors acknowledge cheating at some point in college. The...
A high-profile health scare on stage sparked a ripple of financial questions for touring acts and self-employed profe...
A dramatic security breach at a celebrity home isn’t just news. It offers practical financial lessons on protecting y...
Lawmakers push a roadmap for crypto regulation with an April vote and a May passage deadline. This article breaks dow...